Copyright
©The Author(s) 2020.
World J Gastrointest Pathophysiol. Apr 12, 2020; 11(2): 32-42
Published online Apr 12, 2020. doi: 10.4291/wjgp.v11.i2.32
Published online Apr 12, 2020. doi: 10.4291/wjgp.v11.i2.32
Figure 2 Flow chart depicting the switch to alternative aminosalicylate resulting from the balsalazide shortage, with adverse effect rate of 35.
5% occurring immediately post-switch, which in all cases resolved upon return to balsalazide.
- Citation: van Langenberg DR, Cheng RKY, Garg M. Outcomes of a drug shortage requiring switching in patients with ulcerative colitis. World J Gastrointest Pathophysiol 2020; 11(2): 32-42
- URL: https://www.wjgnet.com/2150-5330/full/v11/i2/32.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v11.i2.32